Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-9.12 Insider Own13.23% Shs Outstand4.70M Perf Week-11.45%
Market Cap5.45M Forward P/E- EPS next Y-2.25 Insider Trans0.00% Shs Float4.08M Perf Month-40.21%
Income-34.63M PEG- EPS next Q-1.74 Inst Own15.86% Short Float2.32% Perf Quarter-90.55%
Sales0.00M P/S- EPS this Y65.64% Inst Trans-61.18% Short Ratio0.27 Perf Half Y-87.65%
Book/sh0.21 P/B5.47 EPS next Y60.00% ROA-141.18% Short Interest0.09M Perf Year-95.00%
Cash/sh5.40 P/C0.21 EPS next 5Y- ROE-946.56% 52W Range1.19 - 22.50 Perf YTD-90.07%
Dividend Est.- P/FCF- EPS past 5Y8.64% ROI-3442.35% 52W High-94.84% Beta0.77
Dividend TTM- Quick Ratio1.03 Sales past 5Y-40.00% Gross Margin84.00% 52W Low-2.52% ATR (14)0.18
Dividend Ex-Date- Current Ratio1.03 EPS Y/Y TTM38.17% Oper. Margin0.00% RSI (14)24.66 Volatility8.66% 9.36%
Employees14 Debt/Eq23.07 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price11.00
Option/ShortNo / Yes LT Debt/Eq0.22 EPS Q/Q-807.89% Payout- Rel Volume0.21 Prev Close1.24
Sales Surprise- EPS Surprise0.23% Sales Q/Q- EarningsMay 09 AMC Avg Volume347.86K Price1.16
SMA20-24.43% SMA50-36.67% SMA200-88.59% Trades Volume72,239 Change-6.45%
Date Action Analyst Rating Change Price Target Change
Jan-25-22Downgrade Stifel Buy → Hold $20 → $6.20
Nov-09-21Upgrade Stifel Hold → Buy $20
Oct-12-21Initiated Credit Suisse Outperform $20
Oct-04-21Initiated Mizuho Buy $20
Sep-21-21Initiated JMP Securities Mkt Outperform $33
Sep-20-21Initiated Stifel Hold $20
Sep-13-21Initiated Cantor Fitzgerald Overweight $50
May-20-24 08:30AM
May-09-24 10:56PM
Apr-09-24 08:00AM
Apr-05-24 12:58PM
08:30AM Loading…
Apr-04-24 08:30AM
Mar-25-24 09:53PM
Feb-05-24 08:30AM
Jan-30-24 09:55AM
Jan-29-24 04:05PM
Jan-25-24 08:00AM
Jan-09-24 08:05AM
Dec-08-23 08:15AM
08:00AM Loading…
Nov-28-23 08:00AM
Nov-15-23 08:00AM
Nov-13-23 04:14PM
Nov-06-23 08:00AM
Oct-24-23 08:00AM
Sep-11-23 08:00AM
Aug-30-23 08:00AM
Aug-11-23 06:05AM
Aug-08-23 04:01PM
Jun-08-23 04:01PM
Jun-07-23 08:00AM
May-31-23 05:43PM
May-26-23 09:00AM
May-25-23 04:50PM
May-09-23 04:01PM
08:00AM Loading…
May-08-23 08:00AM
Apr-26-23 04:01PM
Apr-11-23 08:00AM
Mar-28-23 08:30AM
Mar-08-23 04:01PM
Feb-21-23 08:30AM
Jan-30-23 08:00AM
Jan-05-23 04:01PM
Nov-07-22 04:00PM
Oct-31-22 02:05PM
Oct-26-22 08:00AM
Sep-26-22 08:00AM
Sep-21-22 09:00AM
Sep-14-22 08:00AM
Sep-06-22 08:30AM
Aug-09-22 04:01PM
Aug-08-22 05:30AM
Jun-07-22 08:00AM
Jun-05-22 05:00PM
May-26-22 05:15PM
May-10-22 04:02PM
May-03-22 06:45AM
May-02-22 04:04PM
Apr-04-22 08:30AM
Mar-16-22 04:01PM
Feb-16-22 08:30AM
Feb-15-22 06:53PM
Feb-09-22 04:00PM
Jan-24-22 04:00PM
Nov-24-21 08:00AM
Nov-22-21 08:00AM
Nov-08-21 07:00AM
Nov-04-21 09:08AM
Nov-01-21 04:05PM
Oct-26-21 08:00AM
Oct-07-21 04:30PM
Sep-30-21 04:32PM
Sep-16-21 08:00AM
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SR ONE CAPITAL MANAGEMENT, LLC10% OwnerNov 27 '23Sale0.61609,163369,4571,821,415Nov 29 05:07 PM
WORLAND STEPHEN TChief Executive OfficerAug 11 '23Option Exercise0.5233,79917,575261,225Aug 14 08:00 AM